
Bococizumab
CAS No. 1407495-02-6
Bococizumab( —— )
Catalog No. M36692 CAS No. 1407495-02-6
Bococizumab(PF-04950615) is a humanized mAb against PCSK9 and an inhibitor of the synthesis of PCSK9 in the liver that reduces the amount of low-density lipoprotein cholesterol (LDL-C) in the blood.Bococizumab is used to treat hypercholesterolemia.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 527 | Get Quote |
![]() ![]() |
5MG | 828 | Get Quote |
![]() ![]() |
10MG | 1321 | Get Quote |
![]() ![]() |
25MG | 1822 | Get Quote |
![]() ![]() |
50MG | 2558 | Get Quote |
![]() ![]() |
100MG | 3375 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameBococizumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionBococizumab(PF-04950615) is a humanized mAb against PCSK9 and an inhibitor of the synthesis of PCSK9 in the liver that reduces the amount of low-density lipoprotein cholesterol (LDL-C) in the blood.Bococizumab is used to treat hypercholesterolemia.
-
DescriptionBococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia.
-
In Vitro——
-
In VivoBococizumab (0-100 mg/kg, i.v.) decreases maternal and fetal cholesterol and does not affect rat embryo-fetal development.Animal Model:Pregnant Sprague-Dawley (SD) rats Dosage:0, 10, 30, and 100 mg/kg Administration:Intravenous injection (i.v.)Result:Decreased in fetal cholesterol levels.Showed well tolerance and no effects on ovarian or uterine parameters.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1407495-02-6
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Koutaro Yokote, et al. Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive - Results From a Randomized, Placebo-Controlled, Dose-Ranging Study. Circ J. 2017 Sep 25;81(10):1496-1505. ?
molnova catalog



related products
-
Quercetin 3-O-(6-gal...
Quercetin 3-O-(6''-galloyl)-beta-D-galactopyranoside can effectively induce apoptosis via p53, MAPKs and the mitochondrial apoptotic pathways.
-
5alpha-Cholestan-3-o...
5alpha-Cholestan-3-one(5aCh3) is an intermediate product in cholesterol metabolism, which is elevated in the case of cerebrotendinous xanthomatosis.
-
N-(3-methoxybenzyl)-...
N-(3-methoxybenzyl)-octadecanamide deverts from Maca (Lepidium meyenii Walp.).